Premium
Poor response to hepatitis A vaccination in hematopoietic stem cell transplant recipients
Author(s) -
Adati Elen Monteiro,
Silva Paula Moreira,
Sumita Laura Massami,
Rodrigues Marina de Oliveira,
Zanetti Lilian P.,
Santos Ana Cláudia F.,
Souza Mair P.,
Colturato Vergilio R.,
Machado Clarisse M.
Publication year - 2020
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.13258
Subject(s) - medicine , vaccination , serology , hepatitis a , seroprevalence , immunology , hepatitis a vaccine , antibody , hepatitis
Background Hepatitis A virus (HAV) infection is highly prevalent in developing countries. In countries experiencing a shift from intermediate/high endemicity to low endemicity, the World Health Organization recommends the incorporation of HAV vaccine into the national vaccination calendar for children aged ≥1 year. Since HAV antibodies wane over time, most HSCT revaccination guidelines advise vaccination as optional, following the country recommendation. However, no study has evaluated the serological response to HAV vaccine in allogeneic HSCT recipients. Methods We conducted a prospective study in 46 HSCT recipients who received two doses of inactivated HAV vaccine. Blood samples were taken before vaccination to determine HAV prevalence rates, and before and 4‐6 weeks after the second dose. Specific anti‐HAV antibodies were detected by a competitive commercial enzyme immune assay. Results Patients received the first dose of vaccine at a median of 332.5 (120‐4134) days after HSCT. Median absolute lymphocyte count at vaccination was 1947 (696‐12 500)/mm 3 . The seroprevalence rate was 93.5% at inclusion. Although safe and well tolerated, the serological response to HAV vaccine in susceptible patients was poor (33%), and no boost effect was observed in seropositive patients. Conclusions In areas with intermediate/high seroprevalence of HAV, serology should be recommended prior to referral to vaccination. The mechanisms of antibody interference and how to overcome T‐cell function deficiency need to be better understood in transplant populations receiving HAV vaccine. Alternative schedules of HAV vaccination should be evaluated in prospective trials.